Not available in the U.S.
Flucloxacillin
FLOXAPEN
What it isPenicillinase-resistant isoxazolyl penicillin that inhibits bacterial cell-wall synthesis and resists staphylococcal beta-lactamase.
Why this oneFirst-line antistaphylococcal penicillin for MSSA infections in the UK, Europe, and Australia, analogous to U.S. dicloxacillin and nafcillin.
What limits itNot available in the U.S. and carries a notable risk of delayed cholestatic hepatitis strongly associated with the HLA-B*57:01 allele.
NO BOXED WARNINGS
Principal riskNot FDA-approved (not marketed in the U.S.), so no FDA boxed warning.
Classes and tags
Clinical profile
Open Flucloxacillin in the interactive console ↗
Self-check
- Which HLA allele is linked to flucloxacillin cholestatic hepatitis?
HLA-B*57:01. - Which US agents are analogous to flucloxacillin for MSSA?
Dicloxacillin and nafcillin.